Achillion Pharmaceuticals Newswire

Achillion Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Achillion Pharmaceuticals.

Results 1 - 20 of 315 in Achillion Pharmaceuticals

  1. Data Presented at American Society of Hematology Meeting Demonstrate...Read the original story

    12 hrs ago | Information Technology

    SAN DIEGO, Dec. 05, 2016 -- Achillion Pharmaceuticals, Inc.i 1 2 today announced novel research into complement biology that both expands the understanding of this important emerging area and demonstrates the potential advantage of factor D inhibitors like the companyi 1 2s lead candidate, ACH-4471, may have in treating complement mediated diseases.

    Comment?

  2. Achillion Pharmaceuticals Inc. (ACHN) Receives $11.57 Consensus PT from AnalystsRead the original story w/Photo

    Yesterday | Daily Political

    Shares of Achillion Pharmaceuticals Inc. have been assigned an average recommendation of "Buy" from the ten brokerages that are currently covering the company. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company.

    Comment?

  3. Has The Smart Money Found A Winner in Infoblox Inc (BLOX)?Read the original story w/Photo

    Thursday Dec 1 | Insider Monkey

    ... from 25 on June 30. At the end of this article we will also compare BLOX to other stocks including Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN ), Multi-Color Corporation (NASDAQ: LABL ), and Abaxis Inc (NASDAQ: ABAX ) to get a better sense of its ...

    Comment?

  4. Is Tower Semiconductor Ltd. (USA) (TSEM) A Good Stock To Buy Right Now?Read the original story w/Photo

    Thursday Dec 1 | Insider Monkey

    ... TSEM to other stocks including McEwen Mining Inc (NYSE: MUX ), Infoblox Inc (NYSE: BLOX ), and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN ) to get a better sense of its popularity. At Insider Monkey, we've developed an investment strategy that ...

    Comment?

  5. Achillion Pharmaceuticals Inc. (ACHN) Receives Consensus Rating of "Buy" from AnalystsRead the original story w/Photo

    Wednesday Nov 30 | AmericanBankingNews.com

    Achillion Pharmaceuticals Inc. has received an average rating of "Buy" from the ten research firms that are currently covering the company. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company.

    Comment?

  6. Achillion Announces Initiation Of Patient Dosing By Janssen...Read the original story

    Tuesday Nov 29 | BioSpace

    Achillion Pharmaceuticals, Inc. today announced the start of patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, has been initiated by Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson , in treatment-naive and treatment-experienced patients with chronic hepatitis C virus infection without cirrhosis. This large, international, multi-center study is expected to enroll approximately 300 HCV patients, and is part of Janssen's global development program for JNJ-4178.

    Comment?

  7. Achillion Announces Initiation of Patient Dosing by Janssen in a...Read the original story

    Wednesday Nov 30 | Information Technology

    Achillion Pharmaceuticals, Inc. i 1 2 today announced the start of patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, has been initiated by Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson , in treatment-naive and treatment-experienced patients with chronic hepatitis C virus infection without cirrhosis. This large, international, multi-center study is expected to enroll approximately 300 HCV patients, and is part of Jansseni 1 2s global development program for JNJ-4178.

    Comment?

  8. Alps Advisors Inc. Has $1,411,000 Stake in Achillion Pharmaceuticals Inc.Read the original story w/Photo

    Monday Nov 28 | Daily Political

    Alps Advisors Inc. decreased its position in shares of Achillion Pharmaceuticals Inc. by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission . The institutional investor owned 174,246 shares of the biopharmaceutical company's stock after selling 17,707 shares during the period.

    Comment?

  9. Investigation for Investors in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) AnnouncedRead the original story w/Photo

    Monday Nov 28 | SBWire

    An investigation on behalf of investors of Achillion Pharmaceuticals, Inc. was announced over potential securities laws violations by Achillion Pharmaceuticals in connection certain financial statements. Investors who purchased shares of Achillion Pharmaceuticals, Inc. , have certain options and should contact the Shareholders Foundation at [email protected] or call 858-779-1554.

    Comment?

  10. Zacks Investment Research Downgrades Achillion Pharmaceuticals Inc. (ACHN) to HoldRead the original story w/Photo

    Monday Nov 28 | Daily Political

    ... issued reports about the company. Leerink Swann reaffirmed a market perform rating on shares of Achillion Pharmaceuticals in a research report on Thursday, November 3rd. Jefferies Group reaffirmed a hold rating on shares of Achillion Pharmaceuticals ...

    Comment?

  11. This Metric Says It May Be Time to Buy Achillion Pharmaceuticals, Inc.Read the original story w/Photo

    Saturday Nov 26 | Insider Monkey

    ... pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN ) . Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has experienced an increase in hedge fund interest ...

    Comment?

  12. Research Analysts' Weekly Ratings Changes for Achillion PharmaceuticalsRead the original story w/Photo

    Thursday Nov 24 | AmericanBankingNews.com

    11/22/2016 - Achillion Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. According to Zacks, "Achillion reported narrower-than-expected loss in the third quarter and generated no revenues ...

    Comment?

  13. Zacks Investment Research Downgrades Achillion Pharmaceuticals Inc. (ACHN) to HoldRead the original story

    Tuesday Nov 22 | AmericanBankingNews.com

    ... A number of other brokerages have also weighed in on ACHN. Chardan Capital upgraded shares of Achillion Pharmaceuticals from a "sell" rating to a "neutral" rating and set a $5.00 price objective for the company in a report on Friday, November 4th. ...

    Comment?

  14. Achillion Pharmaceuticals (ACHN) - Research Analysts' Recent Ratings UpdatesRead the original story

    Tuesday Nov 15 | AmericanBankingNews.com

    11/7/2016 - Achillion Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.00 price target on the stock. According to Zacks, "Achillion reported narrower-than-expected loss ...

    Comment?

  15. Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) to Ring The Nasdaq Stock Market Closing BellRead the original story w/Photo

    Monday Nov 14 | GlobeNewswire

    What: Achillion Pharmaceuticals, Inc. , a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases, will visit the Nasdaq MarketSite in Times Square.

    Comment?

  16. Achillion Pharmaceuticals Inc. (ACHN) Stake Held by Legal & General Group PlcRead the original story w/Photo

    Sunday Nov 13 | Daily Political

    Legal & General Group Plc continued to hold its position in shares of Achillion Pharmaceuticals Inc. during the second quarter, Holdings Channel reports. The institutional investor owned 18,010 shares of the biopharmaceutical company's stock at the end of the second quarter.

    Comment?

  17. Achillion Pharmaceuticals Inc. (ACHN) Sees Significant Drop in Short InterestRead the original story

    Saturday Nov 12 | AmericanBankingNews.com

    Achillion Pharmaceuticals Inc. saw a large decline in short interest in October. As of October 31st, there was short interest totalling 11,513,154 shares, a decline of 9.5% from the October 14th total of 12,723,710 shares.

    Comment?

  18. Biotech Stocks Under Scanner a " Anavex Life Sciences, Eleven Biotherapeutics, Achillion Pharma, and...Read the original story w/Photo

    Friday Nov 11 | Freshnews

    The Biotech industry rallied in the final hour of trading on Wednesday, November 09, 2016, as the Nasdaq Biotechnology Index advanced 9%, and was on track for its biggest single-day gain in more than eight years. Ahead of today's trading session, Stock-Callers.com looks at Anavex Life Sciences Corp. , Eleven Biotherapeutics Inc. , Achillion Pharmaceuticals Inc. , and Tokai Pharmaceuticals Inc. to see how they have fared at the closing bell yesterday.

    Comment?

  19. Biotech Stocks Under Scanner -- Anavex Life Sciences, Eleven...Read the original story w/Photo

    Wednesday Nov 9 | PR Newswire

    Ahead of today's trading session, Stock-Callers.com looks at Anavex Life Sciences Corp. , Eleven Biotherapeutics Inc. , Achillion Pharmaceuticals Inc. , and Tokai Pharmaceuticals Inc. to see how they have fared at the closing bell yesterday. You can access of our complimentary research reports on these stocks now at: , declining 0.62%, with a total trading volume of 477,261 shares.

    Comment?

  20. FY2020 EPS Estimates for Achillion Pharmaceuticals Inc. Boosted by FBR & CoRead the original story w/Photo

    Wednesday Nov 9 | AmericanBankingNews.com

    Achillion Pharmaceuticals Inc. - Investment analysts at FBR & Co upped their FY2020 earnings estimates for shares of Achillion Pharmaceuticals in a research note issued on Thursday. FBR & Co analyst C. James now anticipates that the firm will post earnings of per share for the year, up from their prior estimate of .

    Comment?